Marine Collagen Hydrolysates Promote Collagen Synthesis, Viability and Proliferation While Downregulating the Synthesis of Pro-Catabolic Markers in Human Articular Chondrocytes

Abstract

Cartilage is a non-innervated and non-vascularized tissue. It is composed of one main cell type, the chondrocyte, which governs homeostasis within the cartilage tissue, but has low metabolic activity. Articular cartilage undergoes substantial stresses that lead to chondral defects, and inevitably osteoarthritis (OA) due to the low intrinsic repair capacity of cartilage. OA remains an incurable degenerative disease. In this context, several dietary supplements have shown promising results, notably in the relief of OA symptoms. In this study, we investigated the effects of collagen hydrolysates derived from fish skin (Promerim®30 and Promerim®60) and fish cartilage (Promerim®40) on the phenotype and metabolism of human articular chondrocytes (HACs). First, we demonstrated the safety of Promerim® hydrolysates on HACs cultured in monolayers. Then we showed that, Promerim® hydrolysates can increase the HAC viability and proliferation, while decreasing HAC SA-β-galactosidase activity. To evaluate the effect of Promerim® on a more relevant model of culture, HAC were cultured as organoids in the presence of Promerim® hydrolysates with or without IL-1β to mimic an OA environment. In such conditions, Promerim® hydrolysates led to a decrease in the transcript levels of some proteases that play a major role in the development of OA, such as Htra1 and metalloproteinase-1. Promerim® hydrolysates downregulated HtrA1 protein expression. In contrast, the treatment of cartilage organoids with Promerim® hydrolysates increased the neosynthesis of type I collagen (Promerim®30, 40 and 60) and type II collagen isoforms (Promerim®30 and 40), the latter being the major characteristic component of the cartilage extracellular matrix. Altogether, our results demonstrate that the use of Promerim® hydrolysates hold promise as complementary dietary supplements in combination with the current classical treatments or as a preventive therapy to delay the occurrence of OA in humans.

Attenuative effects of collagen peptide from milkfish (Chanos chanos) scales on ovariectomy‐induced osteoporosis

“…Previous research has shown that low‐molecular‐weight collagen peptide or fish collagen peptide is a potential candidate for the treatment of OA that stimulates cartilage regeneration using a rabbit anterior cruciate ligament transection (ACLT) model of induced OA and chondrocytes isolated from a patient with OA (Lee et al, 2021 ; Ohnishi et al, 2013 ). Fish collagen hydrolysates were also shown to enhance collagen production, viability, and proliferation in human articular chondrocytes (Bourdon et al, 2021 ). In addition, OVX mice or rats have previously been used in the study of osteoporosis following menopause (Lemini et al, 2015 ; Strom et al, 2012 ; Zhang et al, 2014 ).…”

Developments for collagen hydrolysates as a multifunctional antioxidant in biomedical domains

“…Marine collagen hydrolysate has recently been reported as a novel natural antioxidant in biomedical applications as an alternative to conventional mammalian (such as bovine and porcine sources) collagen hydrolysates [38]. Aquatic collagen sources have many advantages over land animals, such as weak immunogenicity, biocompatibility, no religious and moral conflicts, and low chances of causing transmissible diseases.…”